Jonathan Gardner
Jonathan Gardner covers the business of biopharmaceuticals for BioPharma Dive, with a focus on how scientific advances and clinical data translate into commercial power, especially in cancer. His coverage stands out for treating trial readouts and licensing deals as inflection points that reshape competitive dynamics, rather than as isolated events. He writes in clear, grounded language that connects mechanisms of action, study design and market strategy in the same frame.
Cancer drug pipelines and antibody-drug conjugates
Gardner’s work zeroes in on oncology pipelines, using individual studies to show how new therapies might change standards of care and market share. In covering Merck’s antibody-drug conjugate licensed from a Chinese partner and tested in a first large global trial, he explains not just that the drug “hits the mark,” but what that means in terms of endpoints, patient populations and the future positioning of the product. His stories stay close to the evidence, unpacking the details of trial design and outcome measures while keeping sight of which competitors, indications and lines of therapy are most at stake. He treats complex modalities like antibody-drug conjugates as business stories rooted in biology, making clear how attributes such as targeting, safety and delivery shape commercial value.
Cross-border licensing and Chinese biotech partnerships
A recurring thread in Gardner’s beat is the flow of innovative drugs and technologies between Chinese biotechs and global pharmaceutical companies. When he writes about a Merck oncology drug licensed from China, he uses the case to show how cross-border deals are restructuring who controls key assets in hot areas like targeted oncology. He pays attention to which company holds development and commercialization rights in different territories, why a Western pharma company turns to a Chinese partner, and what that implies for timelines, competition and access in major markets. His coverage highlights licensing as a strategic tool, not just a legal formality, and makes clear how these alliances can alter both regional and global drug landscapes.
Clinical data with clear commercial stakes
Across his business beat, Gardner treats clinical data as the backbone of valuation, dealmaking and portfolio strategy. In writing about pivotal studies, he explains the strength of the evidence, the stage of development and the remaining regulatory hurdles, then ties those factors directly to questions such as market entry, pricing leverage and label expansion. He is attentive to how a “first big global trial” differs from earlier, smaller studies in terms of the confidence it gives companies to invest, partner or pivot. His stories emphasize competitive context, spelling out which existing therapies could be displaced, where a new drug might realistically fit and how results could shift negotiating power in future transactions.
Deal-driven view of biopharma strategy
Gardner’s lens on the industry is fundamentally deal-driven, treating licensing agreements, co-development pacts and late-stage trial milestones as strategic moves on a longer board. He brings out the way R&D decisions, such as backing a risky oncology modality or betting on a partner’s platform, feed directly into business outcomes like portfolio balance and future revenue streams. Rather than covering the science and the strategy in separate tracks, he uses each story to show how they interact: a global trial does not just test a drug, it tests a company’s bet on a partner, a mechanism and a market. This integrated approach makes his work useful to anyone trying to understand not only what happened in a study or deal, but why it matters for the companies involved and their rivals.
4 more business journalists.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex Smith
Alex Smith focuses on the business impact of enterprise technology, with a distinctive emphasis on AI literacy and skills rather than technical specifications. They write for Technology Record, covering how artificial intelligence and cloud platforms from major providers are turned into concrete programmes for organisations and governments. Their beat sits at the junction of business strategy, national digital policy and large-scale technology partnerships. They report on national AI literacy programmes and public–private partnerships, showing how policy choices, vendor capabilities and skills gaps intersect. On the business beat, they treat AI and cloud as tools for competitiveness, workforce readiness and participation in a data-driven economy. Their concise, announcement-led reporting highlights who is partnering with whom, what programme is being launched, which technologies underpin it and how it changes capability on the ground for executive readers.
Alison Durkee
Alison Durkee focuses on how law, regulation and politics create business risks for major companies and industries. She is a reporter at Forbes, where she writes news-driven explainers on complex legal and regulatory developments and their impact on corporate strategy, reputation and markets. Her coverage centers on companies under scrutiny, especially in technology and other high-growth sectors, and tracks trials, investigations and fast-changing policy fights. She breaks down lawsuits, inquiries and regulatory moves into clear parts, grounded in timelines, filings and official actions. She reports on generative artificial intelligence and other emerging technologies as tests of legal frameworks and corporate risk management, explaining how issues like intellectual property, safety compliance, consumer protection and governance can reshape product roadmaps, partnerships and investor expectations.
Alyson Shontell
Alyson Shontell covers business through the lens of leadership, using in-depth conversations with powerful executives and founders to show how their decisions shape companies, markets, and public life. She is editor in chief at Fortune, overseeing coverage across the masthead while continuing to write selected high-impact pieces. Her core work is long, reported interviews and profiles of CEOs of large companies, dominant tech firms, and fast-growing startups. She focuses on how leaders think, manage risk, make unconventional calls, and handle crises, culture, and the future of work. Her subjects include corporate chiefs, startup founders, and political figures treated as executives. She probes operating detail, governance, internal culture, and trade-offs around growth, disruption, and workplace models, using concrete examples and direct, accessible prose that foregrounds the subject’s voice while pressing for specifics.